Surfactant treatment of neonates with respiratory failure and group B streptococcal infection

Pediatrics

Volumn 106, Issue 5 I, 2000, Pages 957-964

  Herting, Egbert ^a,d   Gefeller, Olaf ^b   Land, Matthias ^b   Van Sonderen, Loekie ^c   Harms, Karsten ^a   Robertson, Bengt ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Group B streptococci; Infants; Neonates; Pediatrics; Pneumonia; Pulmonary surfactant

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; LUNG SURFACTANT EXTRACT;

ARTICLE; BIRTH WEIGHT; BRAIN HEMORRHAGE; CONTROLLED STUDY; HUMAN; INFANT; LUNG GAS EXCHANGE; MAJOR CLINICAL STUDY; OXYGEN CONSUMPTION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME;

EID: 0033753605     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.106.5.957     Document Type: Article

References (31)

1. Early onset group Bstreptococcal sepsis: A current assessment
2. A comparison of early onset group B streptococcal neonatal infection and the respiratory distress syndrome
3. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia
4. Surfactant treatment of full-term newborns with respiratory failure
5. Surfactant therapy in full-term neonates with severe respiratory failure
6. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure: Survanta in term infants study group
7. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: An international randomized clinical trial
8. Early and late surfactant replacement therapy in severe respiratory distress syndrome
9. Randomised European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: Single versus multiple doses of Curosurf
10. Randomized clinical trial of surfactant therapy for neonatal respiratory distress syndrome: Comparison of two treatment regimens with natural surfactant preparations
11. Factors influencing morbidity and mortality in infants with severe respiratory distress syndrome treated with single or multiple doses of a natural porcine surfactant
12. Reducing bias in observational studies using subclassification on the propensity score
13. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomised control group
14. Acute pulmonary radiograph changes in hyaline membrane disease treated with artificial ventilation and positive end-exspiratory pressure (PEEP)
15. Group B streptococcal infections
16. Prevention of perinatal group B streptococcal disease: A public health perspective
17. Revised guidelines for prevention of early-onset group B-streptococcal (GBS) infection
18. High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia
19. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: A randomised controlled trial
20. Comparison of prevention strategies for neonatal group B streptococcal infection: A population based economic analysis
21. Prognostic value of immediate response to surfactant
22. Surfactant replacement therapy for meconium aspiration syndrome
23. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis
24. Host defense functions of surfactant
25. Effect of different surfacrants on pulmonary group B streptococcal infection in premature rabbits
26. Experimental neonatal group B streptococcal pneumonia: Effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits
27. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection
28. Formulating a surfactant therapy for preterm infants who have bacterial pneumonia and respiratory distress syndrome
29. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs
30. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae
31. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B-streptococcal pneumonia